Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had ...
Patients with heart failure who took dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, after undergoing ...
CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Gearing Up for Phase 3 Trial of Tecarfarin Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) is a biopharmaceutical company developing tecarfarin, a ...
News Medical on MSN19h
Heart failure patients benefit from dapagliflozin after TAVR procedurePatients with heart failure who took dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, after undergoing transcatheter aortic valve replacement (TAVR) were significantly less likely ...
A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve ...
The decision to move forward with a heart transplant is made when all other treatment options been unsuccessful.
At two years of follow-up, patients with a poorly functioning tricuspid valve in the heart who received the best available ...
JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, presented results from an expanded cohort of 500 patients in the ALIGN-AR Pivotal Trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback